Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IPO Update: Values Slip As Four More Biopharma Firms Go Public In October

Executive Summary

There were four biopharma IPOs in October – Myovant, Ra, CRISPR and AzurRX – but only one was trading above its offering price by the end of the month, reflecting investor uncertainty about the industry.

Advertisement

Related Content

Biopharma IPOs Gain Momentum As Three More Launch In The US
Start-Up Quarterly Statistics, Q4 2016
IPO Update: Novan, AC Immune End Summer Slowdown As Market Improves
Scrip's Rough Guide To CRISPR Gene Editing
IPO Update: Intellia Launch Shows CRISPR Still Excites While Others Struggle
Can Editas, BeiGene Offerings Redeem US IPO Class Of 2015?
Bayer And CRISPR Form Cutting Edge Gene Editing JV
Gene Editing Deal Broadens Vertex's CF Base, Doubles CRISPR's Cash
Oncobiologics raises $31m for biosimilars; RaNA, Ra, SutroVax add VC cash
Roundup: Three Chinese Deals To Put On Your Radar

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097616

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel